CURATODERM

This brand name is authorized in Austria, Poland, United Kingdom

Active ingredients

The drug CURATODERM contains one active pharmaceutical ingredient (API):

1 Tacalcitol
UNII B3Q63NVN9R - TACALCITOL MONOHYDRATE

Tacalcitol is a vitamin D3 derivative, which inhibits keratinocyte hyper-proliferation and induces differentiation of these cells. The normalisation of these mechanisms is the basis for the efficacy in the treatment of psoriasis.

Read about Tacalcitol

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
CURATODERM Ointment Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
D05AX04 Tacalcitol D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use
Discover more medicines within D05AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 127734, 24541, 24544
Country: PL Rejestru Produktรณw Leczniczych Identifier(s): 100077318

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.